Aptar CSP Technologies has opened a new manufacturing facility in New Jersey, US, to support clinical-stage packaging for oral solid dose forms and capsule-based dry powder inhaler (DPI) drugs using Aptar CSP’s proprietary Activ-Polymer platform and Activ-Blister solutions.
The company claimed that its new facility is current good manufacturing practice (cGMP)-compliant.
They work by limiting exposure to moisture, oxygen, and volatile compounds while also reducing nitrosamine risks.
Activ-Blister incorporates a functional film layer into standard blister formats for dose-level protection.
This method helps preserve each unit by creating a tailored microenvironment within the packaging.
The protection can be adjusted based on the specific stability requirements of individual drug products.
Built in partnership with MOD3 Pharma, the facility offers a broad range of development services.
These include support for early-phase research, production of clinical materials, and stability testing.
The site will also provide full chemistry, manufacturing and controls package, stability studies, and manage clinical supplies.
Aptar’s Activ-Polymer technology is applied across multiple healthcare product categories, the company said.
It is used to shield temperature- or moisture-sensitive items such as medicines, diagnostics, and implants.
Aptar CSP Technologies commercial operations vice-president and general manager Badre Hammond said: “Launching this cGMP facility reinforces our commitment to delivering streamlined access to innovative active material science technologies for patients and pharmaceutical partners.
“By offering early-stage clinical services with custom-designed equipment, we simplify adoption, eliminate implementation barriers, and help avoid lengthy reformulation or repackaging efforts.”
